4^th European Endocrinology and Diabetes Congress

Mikhail G Kolonin is an Associate Professor and Director of the Center for Metabolic and Degenerative Diseases at the University of Texas in Houston. As a Ph.D. from Wayne State University, he pioneered the concept of expressing peptides disrupting protein interactions in animals. As a Postdoctoral fellow at MD Anderson Cancer Center, he screened combinatorial libraries to identify druggable cell surface markers. Based on this approach, he has invented experimental therapeutics for obesity and cancer. He is an Author of over 60 publications and has editorial positions with Molecular Carcinogenesis and Cancer Research. He is endowed with a Distinguished University Chair in Metabolic Disease Research.

He has invented experimental therapeutics for obesity and cancer. He is an Author of over 60 publications and has editorial positions with Molecular Carcinogenesis and Cancer Research. He is endowed with a Distinguished University Chair in Metabolic Disease Research.

Dr. Arturo Solís Herrera, MD, PhD., has been Graduated from Institute Polytechnic Nacional, from CDMX, in 1978 as Medicine Doctor, with the specialties including Ophthalmology, in the National University of Mexico, and Neuro-Ophthalmology, at INNN, México. Later on he obtained his Master Science Degree from University of Aguascalientes, México, and thereafter a PhD in Pharmacology, Universidad de Guadalajara, México. Dr. Solís Herrera is director and founder of Human Photosynthesis® Research Center, in Ags., México, in 2007; where he has continued his research until today.

The discovery of a biochemical process, that from a molecule that exists on the skin, hair and coating the human retina but can be produced artificially, (melanin or polihidroxiindol), is capable of breaking the molecule water, separating the hydrogen and oxygen and extracting energy from this process. The raw material of this invention is abundant in nature, as its core components are water and a molecule that exists in the skin, hair and the lining of the human retina, but that can be produced artificially: melanin or polihidroxiindol.

Douglas N Ishii received his BA in Biochemistry from the University of California, Berkeley, and Ph.D. in Pharmacology from Stanford University Medical School and conducted Postdoctoral work in Neurobiology at Stanford. He became an Assistant and then Associate Professor of Pharmacology at Columbia University, New York City. He is a Professor of Biomedical Sciences at Colorado State University. He served on various scientific study sections for the National Science Foundation, the National Institutes of Health, and The Juvenile Diabetes International Foundation. Press coverage on his laboratory’s research on the pathogenesis of diabetic neurological complications, and the cause of brain atrophy in Alzheimer’s disease, include articles in Der Spiegel, Hong Kong Standard, NY Times, LA Times, Denver Post, Chicago Tribune, ABC News, Forbes News, USA. Today, National Public Radio, and elsewhere. Nineteen patients were awarded based on this research.

Laboratory research on the pathogenesis of diabetic neurological complications, and the cause of brain atrophy in Alzheimer’s disease.

Dr. Ian James Martins is an Editor/Reviewer for Open Acess Pub/MDPI journals and various other international journals. Advisory Board Member for Photon Journal. Fellow of the International Agency for Standards and Ratings (IASR). Conferred with the RICHARD KUHN RESEARCH AWARD-2015 ENDOCRINOLOGY AND METABOLISM. Chief Editor for International Journal of Diabetes Research (2014-2018), Research and Reviews

Dr. Ian James Martins is an Editor/Reveiwer for Open Acess Pub/MDPI journals and various other international journals. Advisory Board Member for Photon Journal. Fellow of International Agency for Standards and Ratings (IASR). Conferred with the RICHARD KUHN RESEARCH AWARD-2015 ENDOCRINOLOGY AND METABOLISM. Chief Editor for International Journal of Diabetes Research (2014-2018), Research and Reviews

Gerald C Hsu received an honourable PhD in mathematics and majored in engineering at MIT. He attended different universities over 17 years and studied seven academic disciplines. He has spent 20,000 hours in T2D research. First, he studied six metabolic diseases and food nutrition during 2010-2013, then conducted research during 2014-2018. His approach is “math-physics and quantitative medicine” based on mathematics, physics, engineering modelling, signal processing, computer science, big data analytics, statistics, machine learning, and AI. His main focus is on preventive medicine using prediction tools. He believes that the better the prediction, the more control you have.

His approach is “math-physics and quantitative medicine” based on mathematics, physics, engineering modeling, signal processing, computer science, big data analytics, statistics, machine learning, and AI.

Professional skills: working in multicultural contexts applying participatory and consultative methods; natural coordinator and communicator; dynamic, self-reliant and adaptable; proven ability to quickly develop situational and technical understanding, deliver results in a short time, work independently or as part of a team; negotiation and communication skills dealing with government officials, national and international agencies, local and institutional counterparts, donors and general public.

Nutrition, Public health, HIV/AIDS, reproductive health, gender, WASH, communicable diseases, PHC and community empowerment.

Experienced Chief Executive Officer and Director with a demonstrated history of working in the Medical Device and Healthcare Industry. Skilled in Sales and Marketing, Medical Devices, Management, and Capital Equipment including MRI. Experienced in Diabetes and diabetic complications especially retinopathy, neuropathy and otitis externa.

Diabetes